107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC

Key Points

• Great Lakes Advisors LLC initiated a position in Roivant Sciences by purchasing 107,786 shares worth approximately $3.8 million. Institutional investors and hedge funds collectively own 64.76% of the company.
• Roivant shares opened at $36.84, near their 52-week high of $37.97. The company beat quarterly EPS expectations, reporting a loss of $0.26 per share versus the $0.30 expected, although revenue of $1.44 million fell short of estimates.
• Analyst sentiment remains favorable, with a “Moderate Buy” consensus and an average price target of $35.14, while several firms recently raised their targets. However, insiders sold roughly 2.52 million shares worth $87.7 million over the past 90 days.

Great Lakes Advisors LLC purchased a new position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 107,786 shares of the company's stock, valued at approximately $3,815,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. boosted its position in shares of Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company's stock valued at $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after buying an additional 583 shares during the period. Parallel Advisors LLC boosted its position in Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company's stock worth $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC acquired a new stake in Roivant Sciences during the 4th quarter worth about $47,000. Finally, Bessemer Group Inc. grew its stake in Roivant Sciences by 21.8% during the 1st quarter. Bessemer Group Inc. now owns 2,465 shares of the company's stock valued at $69,000 after acquiring an additional 441 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $36.84 on Friday. Roivant Sciences Ltd. has a fifty-two week low of $11.54 and a fifty-two week high of $37.97. The stock's 50-day moving average is $34.48 and its two-hundred day moving average is $30.38. The firm has a market cap of $26.61 billion, a P/E ratio of -69.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, research analysts expect that Roivant Sciences Ltd. will post -2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ROIV. HC Wainwright upped their target price on Roivant Sciences from $34.00 to $41.00 and gave the company a "buy" rating in a report on Friday, August 7th. Citigroup boosted their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a "buy" rating in a research report on Monday, August 10th. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a research note on Thursday, August 6th. Piper Sandler reiterated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Roivant Sciences currently has an average rating of "Moderate Buy" and an average price target of $35.14.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, insider Mayukh Sukhatme sold 284,707 shares of the business's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider directly owned 18,630,739 shares of the company's stock, valued at $675,364,288.75. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total transaction of $6,632,000.00. Following the transaction, the chief executive officer owned 1,613,063 shares in the company, valued at approximately $53,489,169.08. This trade represents a 11.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,520,739 shares of company stock worth $87,746,445 in the last ninety days. Insiders own 8.80% of the company's stock.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source